68Ga-Pentixafor PET/MRI for Treatment Response Assessment in Mantle Cell Lymphoma: Comparison Between Changes in Lesion CXCR4 Expression on PET and Lesion Size and Diffusivity on MRI.
Marius E MayerhoeferMarkus RadererMichael WeberWolfgang LammBarbara KiesewetterMarcus HackerLukas NicsStefan SchmitlDoris LeithnerHans-Juergen WesterAlexander HaugPublished in: Clinical nuclear medicine (2023)
In MCL patients, 68Ga-pentixafor PET may be superior for assessment of complete remission status than anatomic MRI using lesion size criteria, especially at the end of treatment.
Keyphrases
- pet ct
- contrast enhanced
- positron emission tomography
- magnetic resonance imaging
- computed tomography
- end stage renal disease
- diffusion weighted imaging
- chronic kidney disease
- ejection fraction
- newly diagnosed
- poor prognosis
- pet imaging
- peritoneal dialysis
- prognostic factors
- magnetic resonance
- rheumatoid arthritis
- disease activity
- patient reported
- binding protein
- ulcerative colitis